Georgetown University (GU) has supported a successful NIH/NCI funded multidisciplinary program in cancer treatment research for the past 20 years, integrating medical oncology, surgery and radiation oncology within the Lombardi Comprehensive Cancer Center (LCCC). A novel aspect of this research has been focused on developing radiation sensitizing strategies. Molecular targets for radiation sensitization (and chemosensitization) of cancers have been recognized as a significant new area for drug development research, with potential for improving local tumor control, lower treatment-related morbidities and enhanced therapeutic ratio. Furthermore, industry interest has focused on the potential market for such agents, estimated to be in excess of $10 billion annually. In this planning grant application, institutional commitment of personnel, space and shared resources, as well as commitments by two industrial partners (a medical device manufacturer and a biotechnology company) of financial support will provide the initial critical structure for this program. In the performance of the aims in this application, a third partner will be identified, a partner meeting will be planned and scheduled, strategic planning, patent and publication policies will be developed. Successful competition and completion of the aims of this planning application will allow for the next step in AP4 center development.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory Grants--Cooperative Agreements (U56)
Project #
1U56CA109954-01
Application #
6830482
Study Section
Special Emphasis Panel (ZCA1-SRRB-D (M1))
Program Officer
Johnson, Jill
Project Start
2004-07-01
Project End
2006-06-30
Budget Start
2004-07-01
Budget End
2006-06-30
Support Year
1
Fiscal Year
2004
Total Cost
$77,600
Indirect Cost
Name
Georgetown University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057